July 2, 2019 07:30 AM EDT
Financing

SV joins CRUK on a $250M-plus fund with an eye on de­vel­op­ing new can­cer drugs

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Unit­ed­Health Group CEO An­drew Wit­ty steps down

A service from the Financial Times